XMVA09

XMVA09 is an investigational gene therapy delivered via adeno-associated virus (AAV) vector for the treatment of ophthalmic diseases, specifically wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The therapy utilizes a novel AAV shell designed for intravitreal injection, enabling targeted delivery to neovascular lesions in the retina. It encodes a bispecific antibody that simultaneously targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang2), both key mediators of pathological angiogenesis in retinal diseases. By inhibiting these pathways, XMVA09 aims to reduce abnormal blood vessel growth and leakage associated with wAMD and DME. Preclinical studies have demonstrated safety and efficacy in animal models, while early clinical data suggest promising safety, tolerability, low immunogenicity due to its dual-antibody design and new AAV shell technology, as well as potential therapeutic benefit[1][6][9].